価格表

在庫・価格 : 2025年04月26日 12時49分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
α-Galactosylceramide <α-Gal-Cer>
データシート※最新のデータシートでない場合があります
KRN7000 KRNフナコシ
フナコシ(株)
1 mg ¥15,000 3個以上 追加

在庫・価格 : 2025年04月26日 12時49分 現在

α-Galactosylceramide <α-Gal-Cer>

  • 商品コード:KRN7000
  • メーカー:KRN
  • 包装:1mg
  • 価格: ¥15,000
  • 在庫:3個以上
使用文献
No. 文献情報 備考 参照
1 Yamamura T. [Synthetic glycolipid ligands as novel therapeutics for multiple sclerosis]. Rinsho Shinkeigaku 2005 Nov;45(11):909-11
Yamamura T
2005/01/01
PubMed
2 Bharhani MS et al. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis. Int. Immunol. 2009 Jul;21(7):859-70
Bharhani MS et al
2009/01/01
PubMed
3 Chen YG et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J. Immunol. 2005 Feb;174(3):1196-204
Chen YG et al
2005/01/01
PubMed
4 Cao Z et al. Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor. Am. J. Physiol. Gastrointest. Liver Physiol. 2009 Aug;297(2):G249-58
Cao Z et al
2009/01/01
PubMed
5 Ly D et al. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes. Clin. Exp. Immunol. 2010 May;160(2):185-98
Ly D et al
2010/01/01
PubMed
6 Kunii N et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 2009 Jun;100(6):1092-8
Kunii N et al
2009/01/01
PubMed
7 Zeng D et al. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest. 2003 Oct;112(8):1211-22
Zeng D et al
2003/01/01
PubMed
8 Lindqvist M et al. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 2009 May;182(10):6435-43
Lindqvist M et al
2009/01/01
PubMed
9 Ho LP et al. Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur. J. Immunol. 2008 Jul;38(7):1913-22
Ho LP et al
2008/01/01
PubMed
10 Sasakawa A et al. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment. J. Hepatol. 2009 Jun;50(6):1155-62
Sasakawa A et al
2009/01/01
PubMed
11 Ishikawa A et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 2005 Mar;11(5):1910-7
Ishikawa A et al
2005/01/01
PubMed
12 Miellot A et al. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur. J. Immunol. 2005 Dec;35(12):3704-13
Miellot A et al
2005/01/01
PubMed
13 Choi YS et al. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine 2008 Oct;26(46):5855-63
Choi YS et al
2008/01/01
PubMed
14 Kawano T et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 1999 Oct;59(20):5102-5
Kawano T et al
1999/01/01
PubMed
15 Kobayashi S et al. Impaired IFN-gamma production of Valpha24 NKT cells in non-remitting sarcoidosis. Int. Immunol. 2004 Feb;16(2):215-22
Kobayashi S et al
2004/01/01
PubMed
16 Nakagawa R et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res. 1998 Mar;58(6):1202-7
Nakagawa R et al
1998/01/01
PubMed
17 Nieuwenhuis EE et al. Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J. Clin. Invest. 2009 May;119(5):1241-50
Nieuwenhuis EE et al
2009/01/01
PubMed
18 Hayakawa Y et al. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2003 Aug;100(16):9464-9
Hayakawa Y et al
2003/01/01
PubMed
19 Grajewski RS et al. Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J. Immunol. 2008 Oct;181(7):4791-7
Grajewski RS et al
2008/01/01
PubMed
20 Saubermann LJ et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000 Jul;119(1):119-28
Saubermann LJ et al
2000/01/01
PubMed
21 Azakami K et al. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 2009 Oct;114(15):3208-15
Azakami K et al
2009/01/01
PubMed
22 Schmieg J et al. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J. Exp. Med. 2003 Dec;198(11):1631-41
Schmieg J et al
2003/01/01
PubMed
23 Hachem P et al. Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma. Eur. J. Immunol. 2005 Oct;35(10):2793-802
Hachem P et al
2005/01/01
PubMed
24 Looringh van Beeck FA et al. Functional CD1d and/or NKT cell invariant chain transcript in horse, pig, African elephant and guinea pig, but not in ruminants. Mol. Immunol. 2009 Apr;46(7):1424-31
Looringh van Beeck FA et al
2009/01/01
PubMed
25 Shimizu K et al. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J. Immunol. 2007 Mar;178(5):2853-61
Shimizu K et al
2007/01/01
PubMed
26 McWilliams JA et al. Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine 2010 Feb;28(6):1468-76
McWilliams JA et al
2010/01/01
PubMed
27 Tashiro T et al. Induction of Th1-biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells. Int. Immunol. 2010 Apr;22(4):319-28
Tashiro T et al
2010/01/01
PubMed
28 Hattori T et al. Antitumor effect of whole body hyperthermia with alpha-galactosylceramide in a subcutaneous tumor model of colon cancer. Int J Hyperthermia 2007 Nov;23(7):591-8
Hattori T et al
2007/01/01
PubMed
29 Shimizu K et al. Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells. J. Immunol. 2006 Sep;177(5):3484-92
Shimizu K et al
2006/01/01
PubMed
30 Venkataswamy MM et al. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 2009 Aug;183(3):1644-56
Venkataswamy MM et al
2009/01/01
PubMed
31 Chackerian A et al. Activation of NKT cells protects mice from tuberculosis. Infect. Immun. 2002 Nov;70(11):6302-9
Chackerian A et al
2002/01/01
PubMed
32 van Puijvelde GH et al. Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb. Haemost. 2009 Aug;102(2):223-30
van Puijvelde GH et al
2009/01/01
PubMed
33 Thapa P et al. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 2009 May;27(25-26):3484-8
Thapa P et al
2009/01/01
PubMed
34 Balreira A et al. Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness. Immunobiology 2010 Jun;215(6):505-13
Balreira A et al
2010/01/01
PubMed
35 Freigang S et al. Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice. J. Clin. Invest. 2010 Jun;120(6):1873-84
Freigang S et al
2010/01/01
PubMed
36 Inoue H et al. alpha-Galactosylceramide (AGL-517) treatment protects mice from lethal irradiation. Exp. Hematol. 1997 Aug;25(9):935-44
Inoue H et al
1997/01/01
PubMed
  • No.: 1
  • 文献情報:
    Yamamura T. [Synthetic glycolipid ligands as novel therapeutics for multiple sclerosis]. Rinsho Shinkeigaku 2005 Nov;45(11):909-11
    Yamamura T
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Bharhani MS et al. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis. Int. Immunol. 2009 Jul;21(7):859-70
    Bharhani MS et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Chen YG et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J. Immunol. 2005 Feb;174(3):1196-204
    Chen YG et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Cao Z et al. Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor. Am. J. Physiol. Gastrointest. Liver Physiol. 2009 Aug;297(2):G249-58
    Cao Z et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Ly D et al. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes. Clin. Exp. Immunol. 2010 May;160(2):185-98
    Ly D et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Kunii N et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 2009 Jun;100(6):1092-8
    Kunii N et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Zeng D et al. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest. 2003 Oct;112(8):1211-22
    Zeng D et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Lindqvist M et al. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 2009 May;182(10):6435-43
    Lindqvist M et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Ho LP et al. Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur. J. Immunol. 2008 Jul;38(7):1913-22
    Ho LP et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Sasakawa A et al. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment. J. Hepatol. 2009 Jun;50(6):1155-62
    Sasakawa A et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Ishikawa A et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 2005 Mar;11(5):1910-7
    Ishikawa A et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Miellot A et al. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur. J. Immunol. 2005 Dec;35(12):3704-13
    Miellot A et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Choi YS et al. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine 2008 Oct;26(46):5855-63
    Choi YS et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Kawano T et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 1999 Oct;59(20):5102-5
    Kawano T et al
    1999/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Kobayashi S et al. Impaired IFN-gamma production of Valpha24 NKT cells in non-remitting sarcoidosis. Int. Immunol. 2004 Feb;16(2):215-22
    Kobayashi S et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Nakagawa R et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res. 1998 Mar;58(6):1202-7
    Nakagawa R et al
    1998/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Nieuwenhuis EE et al. Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J. Clin. Invest. 2009 May;119(5):1241-50
    Nieuwenhuis EE et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Hayakawa Y et al. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2003 Aug;100(16):9464-9
    Hayakawa Y et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Grajewski RS et al. Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J. Immunol. 2008 Oct;181(7):4791-7
    Grajewski RS et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Saubermann LJ et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000 Jul;119(1):119-28
    Saubermann LJ et al
    2000/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Azakami K et al. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 2009 Oct;114(15):3208-15
    Azakami K et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Schmieg J et al. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J. Exp. Med. 2003 Dec;198(11):1631-41
    Schmieg J et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Hachem P et al. Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma. Eur. J. Immunol. 2005 Oct;35(10):2793-802
    Hachem P et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Looringh van Beeck FA et al. Functional CD1d and/or NKT cell invariant chain transcript in horse, pig, African elephant and guinea pig, but not in ruminants. Mol. Immunol. 2009 Apr;46(7):1424-31
    Looringh van Beeck FA et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Shimizu K et al. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J. Immunol. 2007 Mar;178(5):2853-61
    Shimizu K et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    McWilliams JA et al. Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine 2010 Feb;28(6):1468-76
    McWilliams JA et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Tashiro T et al. Induction of Th1-biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells. Int. Immunol. 2010 Apr;22(4):319-28
    Tashiro T et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Hattori T et al. Antitumor effect of whole body hyperthermia with alpha-galactosylceramide in a subcutaneous tumor model of colon cancer. Int J Hyperthermia 2007 Nov;23(7):591-8
    Hattori T et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Shimizu K et al. Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells. J. Immunol. 2006 Sep;177(5):3484-92
    Shimizu K et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Venkataswamy MM et al. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 2009 Aug;183(3):1644-56
    Venkataswamy MM et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Chackerian A et al. Activation of NKT cells protects mice from tuberculosis. Infect. Immun. 2002 Nov;70(11):6302-9
    Chackerian A et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    van Puijvelde GH et al. Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb. Haemost. 2009 Aug;102(2):223-30
    van Puijvelde GH et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Thapa P et al. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 2009 May;27(25-26):3484-8
    Thapa P et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 34
  • 文献情報:
    Balreira A et al. Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness. Immunobiology 2010 Jun;215(6):505-13
    Balreira A et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 35
  • 文献情報:
    Freigang S et al. Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice. J. Clin. Invest. 2010 Jun;120(6):1873-84
    Freigang S et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 36
  • 文献情報:
    Inoue H et al. alpha-Galactosylceramide (AGL-517) treatment protects mice from lethal irradiation. Exp. Hematol. 1997 Aug;25(9):935-44
    Inoue H et al
    1997/01/01
  • 備考:
  • 参照:
    PubMed